Medical device company ICU Medical (NASDAQ: ICUI) reported Q1 CY2026 results exceeding the market’s revenue expectations, but sales fell by 12.3% year on year to $525.8 million. Its non-GAAP profit of $1.97 per share was 12.5% above analysts’ consensus estimates.
Is now the time to buy ICUI? Find out in our full research report (it’s free for active Edge members).
ICU Medical (ICUI) Q1 CY2026 Highlights:
- Revenue: $525.8 million vs analyst estimates of $519.6 million (12.3% year-on-year decline, 1.2% beat)
- Adjusted EPS: $1.97 vs analyst estimates of $1.75 (12.5% beat)
- Adjusted EBITDA: $98.68 million vs analyst estimates of $95.92 million (18.8% margin, 2.9% beat)
- Operating Margin: 5.8%, in line with the same quarter last year
- Market Capitalization: $3.08 billion
StockStory’s Take
ICU Medical’s first quarter results in 2026 were marked by outperformance against Wall Street expectations, with revenue and non-GAAP earnings per share both coming in above consensus. Management attributed much of the quarter’s strength to robust growth in the Infusion Systems and consumables businesses, driven by improved installation execution and favorable product mix. CEO Vivek Jain highlighted that “the strongest growth driver was LVP by far and away in the segment,” referencing large volume pumps as a key contributor. Meanwhile, Vital Care revenues declined, partly due to the company’s ongoing efforts to exit non-core product lines and focus resources on its core infusion therapy offerings.
Looking ahead, management believes that continued investment in product innovation, operational efficiency, and a balanced approach to installations will support more stable growth across core segments. CFO Brian Bonnell emphasized that the company’s guidance incorporates both potential headwinds from logistics costs and mitigating factors such as lower tariffs and operational efficiencies. Jain noted, “We expect our consumables and systems businesses to be reliable growers with an industry acceptable profit margin, the tightest and most optimized manufacturing network and each with a multiyear innovation portfolio.” Strategic decisions around the Vital Care portfolio and ongoing product launches are expected to further shape the company’s earnings power in the coming quarters.
Key Insights from Management’s Remarks
Management credited the quarter’s results to strong Infusion Systems performance, a resilient consumables segment, and ongoing portfolio optimization within Vital Care. The shift toward early-year installations also helped offset anticipated volatility.
-
Infusion Systems momentum: The infusion systems business achieved its highest-ever quarterly revenue, with large volume pumps (LVP) cited as the primary growth driver. Management noted that improved synchronization of installation resources led to more balanced performance throughout the year, rather than the previously expected back-half weighting.
-
Consumables segment stability: The consumables business demonstrated steady growth, buoyed by incremental product updates and new 510(k) clearances, such as enhancements to the MicroClave and Neutron connectors and a revised disinfection cap. These moves are intended to address adjacent market needs and strengthen infection control offerings.
-
Vital Care optimization: Revenue in the Vital Care segment declined significantly, reflecting the company’s strategic exit from certain low-margin, non-core product lines, including Japanese surgical commodities. Management signaled ongoing efforts to streamline the segment in pursuit of improved profitability.
-
Product innovation pipeline: ICU Medical received additional 510(k) clearances in Q1 for both consumables and software, including the latest FDA-approved version of its LifeShield safety software, which adds analytics and workflow safety features for enterprise customers.
-
Integration and cost initiatives: The company continued to realize synergies from long-term integration projects and manufacturing plant consolidations, resulting in sequential gross margin improvement. Restructuring and remediation spend is expected to decrease further in the coming quarters as major projects wind down.
Drivers of Future Performance
Management’s outlook for the remainder of the year is shaped by continued product innovation, operational discipline, and careful navigation of external cost pressures.
-
Balanced growth in core segments: Management expects both Infusion Systems and consumables to deliver reliable growth, supported by new product launches and improved installation execution. The company’s focus on upgrading its product portfolio is designed to drive revenue and maintain margin stability.
-
Cost management amid macro headwinds: Anticipated increases in logistics costs, primarily from higher oil and diesel prices, are expected to be largely offset by temporary reductions in U.S. tariffs and accelerated operational efficiencies. Management is not relying on potential tariff refunds in its guidance and continues to monitor the evolving trade policy landscape.
-
Portfolio realignment in Vital Care: The company is actively exiting underperforming product lines and evaluating strategic options within the Vital Care business. These moves are expected to improve overall profitability and support management’s goal of achieving leverage below two times EBITDA over time.
Catalysts in Upcoming Quarters
Going forward, the StockStory team will be tracking (1) the cadence and success of new product rollouts and 510(k) clearances, especially in Infusion Systems and consumables, (2) progress on reducing integration and restructuring expenses as major projects conclude, and (3) continued execution on the Vital Care portfolio optimization strategy. The sustainability of gross margin improvements and the company’s ability to offset external cost pressures will also be closely monitored.
ICU Medical currently trades at $128.15, up from $123.10 just before the earnings. Is there an opportunity in the stock?The answer lies in our full research report (it’s free).
Our Favorite Stocks Right Now
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it's flagging for this month - FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
